Oncology Institute, Inc. 8-K

What Happened

• The Oncology Institute, Inc. filed a Certificate of Amendment with the Delaware Secretary of State on July 28, 2026, changing its corporate name to Starling Oncology, Inc., effective immediately. The company disclosed the change in an 8-K and a Regulation FD press release.
• In connection with the name change, the company's common stock will begin trading on the Nasdaq Stock Market under the new ticker symbol "STLN" on August 3, 2026.

Key Details

• Certificate of Amendment filed: July 28, 2026 (name change effective immediately).
• New Nasdaq trading symbol: STLN, effective August 3, 2026.
• CUSIP remains unchanged: 68236X100.
• No stockholder approval was required under Delaware law because the amendment only changed the company name; stockholders do not need to take any action.

Why It Matters

• This is a corporate rebranding and administrative change; it does not alter shareholder rights, ownership structure, or securities identifiers (CUSIP), so investors’ positions are unchanged.
• The primary investor impact is operational: update watchlists, trading platforms, and any automated systems to the new ticker (STLN) starting August 3, 2026, to ensure continued tracking and trading.